...
首页> 外文期刊>World Journal of Gastroenterology >Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies
【24h】

Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies

机译:在腹水中检测端粒酶活性对诊断消化道恶性肿瘤的优势

获取原文
获取原文并翻译 | 示例

摘要

AIM: To evaluate the diagnostic value of assaying telomerase activity in ascites cells for the differential diagnosis of malignant and non-malignant ascites. METHODS: Ascites from 40 patients with hepatocellular carcinoma (HCC), 31 with non-HCC gastrointestinal carcinoma (CA), and 24 with liver cirrhosis (LC) were analyzed for telomerase activity. The telomerase activities in cell pellets from ascites were measured according to the Telomeric Repeat Amplification Protocol (TRAP) and quantified with a densitometer. RESULTS: Positive telomerase activity was detected in 16 of 31 (52%) CA patients, 10 of 40 (25%) HCC patients, and 1 of 24 (4%) LC patients (P < 0.001). The telomerase activity was higher in the ascites of CA patients than in the ascites of HCC or LC patients (CA: 22.9±5.8, HCC: 6.7±2.5, LC: 1.3±1.3, P= 0.001). Cytology was positive in 18 CA patients (58%) and 1 HCC patient (2.5%), respectively. The positive telomerase activity was not related to patients' age, gender, and ascitic protein concentration, but to white blood count (r= 0.31, P= 0.002), neutrophil count (r = 0.29, P= 0.005), and the C-reactive protein level (r= 0.29, P = 0.018). When the results of both cytological examination and telomerase assay were considered together, the sensitivity increased to 77% for CA patients, 25% for HCC patients, and 48% for all 71 gastrointestinal cancer patients. CONCLUSION: Combining cytological examination of ascites with telomerase activity assay significantly improves the differential diagnosis between malignant and non-malignant ascites.
机译:目的:评估在腹水细胞中检测端粒酶活性对鉴别诊断恶性和非恶性腹水的诊断价值。方法:分析了40例肝细胞癌(HCC),31例非HCC胃肠道癌(CA)和24例肝硬化(LC)患者的腹水端粒酶活性。根据端粒重复扩增协议(TRAP)测量腹水细胞沉淀中的端粒酶活性,并用光密度计定量。结果:31例CA患者中有16例(52%)HCC患者中有16例检测到端粒酶阳性,而LC患者24例(4%)中有1例(40%(25%))检测到端粒酶活性(P <0.001)。 CA患者腹水端粒酶活性高于HCC或LC患者腹水(CA:22.9±5.8,HCC:6.7±2.5,LC:1.3±1.3,P = 0.001)。 18名CA患者(58%)和1名HCC患者(2.5%)的细胞学阳性。端粒酶的阳性活性与患者的年龄,性别和腹水蛋白浓度无关,而与白细胞计数(r = 0.31,P = 0.002),中性粒细胞计数(r = 0.29,P = 0.005)和C-反应蛋白水平(r = 0.29,P = 0.018)。当同时考虑细胞学检查和端粒酶测定的结果时,CA患者的敏感性提高到77%,HCC患者的敏感性提高到25%,所有71位胃肠道癌症患者的敏感性提高到48%。结论:将腹水的细胞学检查与端粒酶活性测定相结合可显着提高恶性和非恶性腹水的鉴别诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号